SPOTLIGHT: Merck reports strong Q1 results

Merck reports strong Q1 results
It appears Merck's current line-up of drugs has filled the void left by the loss of Zocor last year. The company announced strong Q1 results, with worldwide sales at $5.8 billion for the quarter--an increase of 7 percent from the first quarter of 2006. Overall, Merck's first-quarter profit jumped 12 percent, due to strong sales and money earned from product divestitures. Release

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.